References
- Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009; 30(Suppl A):32–S37.
- Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649.
- Kornacki J, Skrzypczak J. Preeclampsia- two manifestations of the same disease. Ginekol Pol. 2008;79(6):432–437.
- Ushiyama A, Kataoka H, Iijima T. Glycocalyx and its involvement in clinical pathophysiologies. J Intensive Care. 2016;4(1):59.
- Dogne S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb Vasc Biol. 2018;38(7):1427–1439.
- Hypertension in Pregnancy American college of obstetricians and gynecologists. report of the american college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–1131.
- Figueras F, Gratacos E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36(2):86–98.
- Weissgerber TL, Garcia-Valencia O, Milic NM, et al. Early onset preeclampsia is associated with glycocalyx degradation and reduced microvascular perfusion. J Am Heart Assoc. 2019;8(4):e010647.
- Romao M, Weel IC, Lifshitz SJ, et al. Elevated hyaluronan and extracellular matrix metalloproteinase inducer levels in women with preeclampsia. Arch Gynecol Obstet. 2014;289(3):575–579.
- Gandley RE, Althouse A, Jeyabalan A, et al. Low soluble syndecan-1 precedes preeclampsia. PLoS One. 2016;11(6):e0157608.
- Szabo S, Xu Y, Romero R, et al. Changes of placental syndecan-1 expression in Preeclampsia and HELLP syndrome. Virchows Arch. 2013;463(3):445–458.
- Szpera-Goździewicz A, Majcherek M, Boruczkowski M, et al. Circulating endothelial cells, circulating endothelial progenitor cells, and von Willebrand factor in pregnancies complicated by hypertensive disorders. Am J Reprod Immunol. 2017;77(3):e12625.
- Mehrabian F, Jazi SM, Javanmard SH, et al. Circulating endothelial cells (CECs) and E- selectin: Predictors of preeclampsia. J Res Med Sci. 2012;17:15–21.
- Chen Q, Wang Y, Li Y, et al. Serum podocalyxin is significantly increased in early-onset preeclampsia and may represent a novel marker of maternal endothelial cell dysfunction. J Hypertens. 2017;35(11):2287–2294.
- Shahul S, Medvedofsky D, Wenger JB, et al. Circulating antiangiogenic factors and myocardial dysfunction in hypertensive disorders of pregnancy. Hypertension. 2016;67(6):1273–1280.
- Wikström A-K, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble FMS- like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007;109(6):1368–1374.
- Crispi F, Dominguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. AJOG. 2006;195(1):201–207.
- Pinheiro CC, Rayol P, Gozzani L, et al. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenat Diagn. 2014;34(11):1084–1092.
- Schlembach D, Wallner W, Sengenberger R, et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol. 2007;29(4):407–413.
- Kornacki J, Wirstlein P, Skrzypczak J. [Concentrations of antiangiogenic factors, triglycerides, glucose and insulin in women with two types of preeclampsia]. Ginekol Pol. 2013;84(9):770–775.
- Guengoer Z, Ekmekci H, Tueten A, et al. Is there any relationship between adipocytokines and angiogenesis factors to address endothelial dysfunction and platelet aggregation in untreated patients with preeclampsia? Arch Gynecol Obstet. 2017;296:495–502.